Return to homepagePandemic Pact

Halting transmission of respiratory viral infections using intranasally administered vaccines

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA352035

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2024
    2027

  • Known Financial Commitments (USD)

    $876,167.53

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    University of Melbourne

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Vaccine design and administration

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Vaccines injected into muscle induce antibodies that circulate throughout the body, but these responses are usually insufficient to block infection in the airways where SARS-CoV-2 infection begins. Furthermore, airway infection provides a route for the virus to reach the brain, causing symptoms associated with ‘long COVID’. To improve protection against COVID-19 transmission, and minimise brain infection, we will investigate intranasal (IN) vaccination to induce strong immunity at the site.